CD85K抗体;CD85K Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using CD85K mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using CD85K mouse mAb (green) and negative control (red).    

  
  

•  

   

     Flow cytometric analysis of Jurkat cells using CD85K mouse mAb (green) and negative control (red).    

  
  

•  

   

     Flow cytometric analysis of THP-1 cells using CD85K mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human esophageal cancer tissues using CD85K mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human stomach cancer tissues using CD85K mouse mAb with DAB staining.    

  
  

CD85K, also known as KIR3DL2 (Killer Cell Immunoglobulin-like Receptor 3DL2), is a transmembrane protein belonging to the immunoglobulin superfamily. It is primarily expressed on natural killer (NK) cells and subsets of T lymphocytes, where it functions as a regulatory receptor modulating immune responses. Structurally, CD85K contains three extracellular immunoglobulin-like domains, a transmembrane region, and a cytoplasmic tail with immunoreceptor tyrosine-based inhibitory motifs (ITIMs). These motifs enable it to transmit inhibitory signals upon ligand binding, counteracting activating signals to maintain immune homeostasis.

CD85K interacts with HLA class I molecules, particularly HLA-A3 and HLA-A11 allotypes, though its ligand specificity may vary. This interaction plays a role in distinguishing healthy cells from infected or malignant cells by monitoring MHC class I expression, a mechanism critical for NK cell tolerance. Dysregulation of CD85K has been implicated in autoimmune disorders, viral evasion, and cancer progression. For example, in cutaneous T-cell lymphomas (CTCL), CD85K is overexpressed on malignant T cells, serving as a diagnostic marker and therapeutic target. Recent studies explore CD85K-targeted monoclonal antibodies and CAR-T cell therapies to exploit its disease-specific expression. Despite functional similarities with other KIR family members, CD85K's unique ligand interactions and tissue-specific roles continue to drive research in immunotherapy and immune regulation.